Collegium Pharmaceutical, Inc. reaffirmed earnings guidance for the full year 2024. With the company?s strong financial performance in the first quarter, the company reaffirming its 2024 financial guidance. The company expects net product revenues in the range of $580 million to $595 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
33.82 USD | -1.05% | +0.45% | +9.88% |
05-13 | Collegium Pharmaceutical Launches $35 Million Accelerated Share Repurchase Program | MT |
05-10 | Needham Downgrades Collegium Pharmaceutical to Hold From Buy | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.88% | 1.12B | |
+38.69% | 723B | |
+34.28% | 595B | |
-4.49% | 369B | |
+20.24% | 332B | |
+2.12% | 282B | |
+17.02% | 244B | |
+9.31% | 208B | |
-5.07% | 205B | |
-0.35% | 168B |
- Stock Market
- Equities
- COLL Stock
- News Collegium Pharmaceutical, Inc.
- Collegium Pharmaceutical, Inc. Reaffirms Earnings Guidance for the Full Year 2024